Authors: Cayman Chemical (MI, USA)
Identifying drugs and developing rapid and accurate diagnostic tests for SARS-CoV-2 are currently at the forefront of the infectious disease research agenda. New developments in the novel space surrounding coronavirus research continue to emerge.
While the COVID-19 pandemic is still in its infancy and vaccines for SARS-CoV-2 are in clinical trials, novel drugs and accurate diagnostic tests are more important than ever. Reliable information is required to identify new infections, including asymptomatic carriers, and provide appropriate care to those with confirmed infections. Screening for neutralizing antibodies against SARS-CoV-2 is also important to track the spread of COVID-19 and the effectiveness of vaccines. Meanwhile, identifying drugs to reduce the impact of inflammatory complications relating to coronavirus and minimizing or blocking SARS-CoV-2 entry and replication are key to limiting severe consequences of infection.
To underpin coronavirus research and enable these key developments, Cayman Chemical (MI, USA) has developed a collection of products, tools, and resources that includes:
- Anti-coronavirus compounds
- Screening libraries and assays for drug discovery
- SARS-CoV-2 detection kits and serological ELISAs
- SARS-CoV-2 neutralizing antibody positive/negative controls
- Contract services
Cayman provides a full suite of coronavirus research and drug discovery tools at your fingertips, as well as on-hand technical support, to help make your research possible.
Learn more about the resources and support Cayman provides to help make your coronavirus research possible.